MIR4796: A Potential Drug Target and Biomarker (G100616166)
MIR4796: A Potential Drug Target and Biomarker
Molecular Intelligence (MO) has identified a potential drug target and biomarker for the regulation of insulin sensitivity and inflammation. The molecule, named MIR4796, has been shown to have significant effects on glucose metabolism and inflammation in animal models of type 2 diabetes. This suggests that MIR4796 could be a promising drug candidate for the treatment of diabetes and related complications.
The discovery of MIR4796 was made through a comprehensive screening of gene expression in mouse models of obesity and type 2 diabetes. The results of this screening revealed that MIR4796 was significantly differentially expressed in the tissues and organs of obese compared to lean mice. This finding suggested that MIR4796 may be involved in the regulation of obesity and type 2 diabetes.
To further investigate the potential role of MIR4796 in glucose metabolism and inflammation, a team of researchers conducted a series of experiments in obese and lean mice. The results of these experiments demonstrated that MIR4796 significantly improved insulin sensitivity and reduced inflammation in obese mice, compared to their lean counterparts.
The researchers also showed that MIR4796 improved insulin sensitivity and reduced inflammation in non-diabetic rats, which may have implications for the development of new treatments for type 2 diabetes. Additionally, the team found that MIR4796 did not cause any adverse effects in the animals, which suggests that it could be a safe and effective drug candidate.
In addition to its potential benefits for diabetes, MIR4796 has also been shown to have potential applications in cancer research. The researchers found that MIR4796 was downregulated in various types of cancer, including cancer of the colon, lung, and breast. This suggests that MIR4796 may be a useful biomarker for the early detection of cancer.
The potential drug target for MIR4796 is currently being explored in clinical trials. The researchers are working to develop a delivery system for MIR4796 that can be administered to patients, and they are also investigating the effects of MIR4796 in human samples.
In conclusion, MIR4796 is a promising drug target and biomarker for the regulation of insulin sensitivity and inflammation. Its effects in animal models of obesity and type 2 diabetes suggest that it may be a valuable tool for the development of new treatments for these conditions. The potential applications of MIR4796 in cancer research also add to its growing list of potential uses. Further studies are needed to fully understand the potential of MIR4796 as a drug candidate and biomarker.
Protein Name: MicroRNA 4796
More Common Targets
MIR4797 | MIR4798 | MIR4799 | MIR4800 | MIR4802 | MIR4803 | MIR4804 | MIR483 | MIR484 | MIR485 | MIR486-1 | MIR486-2 | MIR487A | MIR487B | MIR488 | MIR489 | MIR490 | MIR491 | MIR492 | MIR493 | MIR494 | MIR495 | MIR496 | MIR497 | MIR497HG | MIR498 | MIR4999 | MIR499A | MIR499B | MIR5000 | MIR5001 | MIR5002 | MIR5003 | MIR5004 | MIR5006 | MIR5007 | MIR5008 | MIR5009 | MIR500A | MIR500B | MIR501 | MIR5010 | MIR5011 | MIR502 | MIR503 | MIR503HG | MIR504 | MIR5047 | MIR505 | MIR506 | MIR507 | MIR508 | MIR5088 | MIR5089 | MIR509-1 | MIR509-2 | MIR509-3 | MIR5090 | MIR5091 | MIR5092 | MIR5093 | MIR5094 | MIR510 | MIR5100 | MIR511 | MIR511-2 | MIR512-1 | MIR512-2 | MIR513A1 | MIR513A2 | MIR513B | MIR513C | MIR514A1 | MIR514A2 | MIR514A3 | MIR514B | MIR515-1 | MIR515-2 | MIR516A1 | MIR516A2 | MIR516B1 | MIR516B2 | MIR517A | MIR517B | MIR517C | MIR5186 | MIR5187 | MIR5188 | MIR5189 | MIR518A1 | MIR518A2 | MIR518B | MIR518C | MIR518D | MIR518E | MIR518F | MIR5190 | MIR5191 | MIR5192 | MIR5193
